Comparing Lubiprostone and Prucalopride for Chronic Idiopathic constipation(constipation without a known cause)- Which one works better and is safer?

A Comparative Evaluation Of The Effectiveness And Safety Of Lubiprostone And Prucalopride In Patients With Chronic Idiopathic Constipation: A Randomized Controlled Trial - NIL

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/03/082417

Enrollment

Registered

2025-03-17

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K590- Constipation

Interventions

Intervention1: PRUCALOPRIDE: Prucalopride acts as a selective stimulator of the 5-HT4 receptors.Prucalopride stimulates motility by interacting specifically with 5-HT4 receptors in the GI tract which

Eligibility

Inclusion criteria

Inclusion criteria: Patients with chronic idiopathic constipation Patients between ages 18 to 80 years( male and female)

Exclusion criteria

Exclusion criteria: Patients with Mechanical bowel obstruction Patients with Drug Induced Constipation Secondary causes for constipation such as Hypothyroidism, Cardio vascular disease, Malignancies, etc. Pregnant and Lactating women Other bowel disease such as IBD.

Design outcomes

Primary

Measure	Time frame
Increase in Spontaneous Bowel Movement per weekTimepoint: Within 3 week of treatment	—

Secondary

Measure	Time frame
To determine any ADR and its severityTimepoint: Within 3 weeks of treatment	—

Countries

India

Contacts

Public ContactDr Shine Sadasivan

Amrita Institute of Medical Sciences and Research Centre

meenu.vijayan@gmail.com7907989335

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026